AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period C (2012 to 2017)
Number of subjects: 1996
Study 34818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score correlation with 2-year NRM (2000 to 2011)
Number of subjects: 1996
Study 34818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings from the study
Number of subjects: 1996
Study 34818921 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hypnosis
Number of subjects: 1049
Study 34818965 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone
Number of subjects: 13
Study 34818965 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with pomalidomide, carfilzomide, and low-dose dexamethasone
Number of subjects: 13
Study 34819019 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV infection
Number of subjects: 58
Study 34819039 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat monotherapy (3 mg/qw, 5 mg/qw, or 10 mg/q2w)
Number of subjects: 12
Study 34819039 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat combined with exemestane (5 mg/qw + 25 mg/qd)
Number of subjects: 12
Study 34819039 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat monotherapy and combined entinostat/exemestane
Number of subjects: 12
Study 34819116 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment in addition to treatment as usual (TAU) - 5 sessions of 30 minutes each, using soft specific palpatory techniques on the diaphragm, digestive system, and cervical region.
Number of subjects: 72
Study 34819116 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only.
Number of subjects: 72
Study 34819117 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat mini-program-based lactation consultant intervention
Number of subjects: 12
Study 34819138 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue (AT) around the anal fistula tract
Number of subjects: 27
Study 34819138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured AT-MSCs in the responder group
Number of subjects: 27
Study 34819138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured AT-MSCs in the non-responder group
Number of subjects: 27
Study 34819138 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-MSCs of responders
Number of subjects: 27
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to Helicobacter pylori
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to hepatitis A virus (HAV)
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall asthma prevalence
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted seroprevalence of H. pylori
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted seroprevalence of HAV
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis stratified by Hispanic/Latino background
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis restricted to individuals with spirometry-defined COPD
Number of subjects: 12471
Study 34819160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions by smoking and nativity
Number of subjects: 12471
Study 34819278 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHP (Children and Young People's Health Partnership) model of care
Number of subjects: 2138
Study 34819278 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2138
Study 34819278 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHP model of care
Number of subjects: 2138
Study 34819277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program (DiPEP) package including intensive intervention classes, diabetes prevention brochure, exercise calendar, and food record booklet
Number of subjects: 448
Study 34819277 — intervention group
Group type: COMPARATOR
Intervention: Diabetes prevention brochure
Number of subjects: 448
Study 34819284 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic adaptation (performing pointing tasks while wearing glasses shifting optical axis of 10 degrees towards the right side)
Number of subjects: 28
Study 34819284 — intervention group
Group type: COMPARATOR
Intervention: Control (performing the same procedure while wearing neutral glasses without optical deviation)
Number of subjects: 28
Study 34819613 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PBR (Perfused Boundary Region) indicates reduced glycocalyx thickness.
Number of subjects: 297
Study 34819613 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexes of microvascular perfusion including red blood cells filling (RBCF) and functional microvascular density.
Number of subjects: 297
Study 34819613 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of myocardial deformation by speckle-tracking imaging, namely global longitudinal strain (GLS) and percentage changes between peak twisting and untwisting at mitral valve opening (%dpTw-Utw).
Number of subjects: 297
Study 34819793 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) supplementation
Number of subjects: 67
Study 34819793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DHA supplementation)
Number of subjects: 67
Study 34819906 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles
Number of subjects: 0
Study 34819911 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34820133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin therapy
Number of subjects: 600
Study 34820927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0
Study 34820927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34821990 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-yellow pattern visually evoked potentials (BY-VEP) recorded using a video projector (DLP technology) with a blue checkerboard pattern (460 nm) for 200 ms superimposed on a bright yellow background (574 nm).
Number of subjects: 126
Study 34821990 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-yellow pattern visually evoked potentials (BY-VEP) recorded using a video projector (DLP technology).
Number of subjects: 126
Study 34822023 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neutrophil gelatinase associated lipocalin (NGAL) levels measured at 6 and 24 hours post-surgery.
Number of subjects: 60
Study 34822023 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative measurements including plasma creatinine, blood urinary nitrogen, plasma lactate, urine output, and NGAL.
Number of subjects: 60
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 260
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 260
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adaptive skills and high aberrant behaviors in children
Number of subjects: 260
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's internalized disorders
Number of subjects: 260
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's externalized disorders
Number of subjects: 260
Study 34822048 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental factors (family association, training in ASD, disruption in professional activity)
Number of subjects: 260
Study 34822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Peace of Mind Program intervention
Number of subjects: 4402
Study 34822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Peace of Mind Program intervention (completed)
Number of subjects: 4402
Study 34822118 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (usual care)
Number of subjects: 4402
Study 34822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period
Number of subjects: 4402
Study 34822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed intervention
Number of subjects: 4402
Study 34822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey assessing CFIR constructs
Number of subjects: 4402
Study 34822128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0
Study 34822128 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of treatment
Number of subjects: 0
Study 34823566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing implants
Number of subjects: 1500
Study 34824054 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma patients (n=418)
Number of subjects: 605
Study 34824054 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid (OCS) use
Number of subjects: 605
Study 34824054 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants and mild-to-moderate asthma patients
Number of subjects: 605
Study 34824109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists integrated into the ED team providing pharmaceutical care services such as medication reconciliation, review and/or counselling.
Number of subjects: 0
Study 34824109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists integrated into the ED team.
Number of subjects: 0
Study 34824124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3 g of fosfomycin
Number of subjects: 1120
Study 34824124 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of 3 g of fosfomycin o.d.
Number of subjects: 1120
Study 34824124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of pivmecillinam 400 mg three times per day (t.i.d)
Number of subjects: 1120
Study 34824124 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of nitrofurantoin 100 mg t.i.d.
Number of subjects: 1120
Study 34824124 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1120
Study 34824133 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-guided endovascular super-selective intra-arterial infusion of mesenchymal stem cells loaded with Delta-24 (MSC-D24)
Number of subjects: 1
Study 34824133 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-guided endovascular super-selective intra-arterial infusion of MSC-D24
Number of subjects: 1
Study 34824139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-score LSM analyses
Number of subjects: 180
Study 34824139 — intervention group
Group type: COMPARATOR
Intervention: Total NIHSS score
Number of subjects: 180
Study 34824596 — intervention group
Group type: EXPERIMENTAL
Intervention: Janssen Ad26.COV2.S vaccine
Number of subjects: 0
Study 34824596 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 34825149 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved WASH
Number of subjects: 303
Study 34825149 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma intestinal fatty-acid binding protein
Number of subjects: 303
Study 34825149 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase
Number of subjects: 303
Study 34825149 — intervention group
Group type: EXPERIMENTAL
Intervention: EED biomarkers
Number of subjects: 303
Study 34825149 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-level WASH interventions
Number of subjects: 303
Study 34825279 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making practices in hospice interdisciplinary team meetings
Number of subjects: 0
Study 34825279 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes of hospice staff toward shared decision making measured by the revised Leeds Attitude to Concordance scale (LatConII)
Number of subjects: 0
Study 34825279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods analysis of hospice staff perceptions
Number of subjects: 0
Study 34825942 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide/dexamethasone (E-Pd)
Number of subjects: 440
Study 34825942 — intervention group
Group type: COMPARATOR
Intervention: Elotuzumab plus lenalidomide/dexamethasone (Ld)
Number of subjects: 440
Study 34825972 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA on day 1
Number of subjects: 956
Study 34825972 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG on day 1
Number of subjects: 956
Study 34825972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of IgG on day 1
Number of subjects: 956
Study 34825972 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM on day 1
Number of subjects: 956
Study 34825996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 510
Study 34825996 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 510
Study 34825996 — intervention group
Group type: COMPARATOR
Intervention: Patients with withholding/withdrawal decision
Number of subjects: 510
Study 34825996 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers (nurses and physicians)
Number of subjects: 510
Study 34826060 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedures (REPs) via blood clots
Number of subjects: 10
Study 34826114 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 6.25 mg once daily for 28 days
Number of subjects: 24
Study 34826122 — intervention group
Group type: EXPERIMENTAL
Intervention: FLECTOR (diclofenac epolamine topical system)
Number of subjects: 104
Study 34826124 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 26
Study 34826124 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 26
Study 34826124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34826192 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 156
Study 34826353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment with significant Phe reduction
Number of subjects: 156
Study 34826409 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34826412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-G-Len (polatuzumab vedotin 1.4 mg/kg + lenalidomide 20 mg + obinutuzumab 1000 mg)
Number of subjects: 56
Study 34826411 — intervention group
Group type: EXPERIMENTAL
Intervention: BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax)
Number of subjects: 39
Study 34827232 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1850
Study 34827232 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1850
Study 34828655 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 34
Study 34828655 — intervention group
Group type: COMPARATOR
Intervention: 60% oxygen
Number of subjects: 34
Study 34828724 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (Rhythmic Reading Training - RRT)
Number of subjects: 30
Study 34828724 — intervention group
Group type: COMPARATOR
Intervention: In-presence rehabilitation (Rhythmic Reading Training - RRT)
Number of subjects: 30
Study 34829796 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP Inhibitors
Number of subjects: 0
Study 34829796 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34829967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacteriotherapy (Vivomixx® in EU, Visbiome® in USA) for 6 months
Number of subjects: 20
Study 34829967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34830829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests (Auditory Verbal Learning Test, Letter Fluency Test, Category Fluency Test, Trail Making Test) in TC survivors
Number of subjects: 184
Study 34830829 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tests in healthy controls
Number of subjects: 184
Study 34830984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and Abiraterone
Number of subjects: 142
Study 34830984 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Abiraterone
Number of subjects: 142
Study 34831051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels <30 mg/dL
Number of subjects: 192
Study 34831051 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) levels ≥30 mg/dL
Number of subjects: 192
Study 34831060 — intervention group
Group type: EXPERIMENTAL
Intervention: Early gestational placental-derived mesenchymal stem/stromal cells (PMSCs)
Number of subjects: 0
Study 34831332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild prolonged hypoglycemia (blood glucose maintained at 2.8 mmol/L for 1 hour)
Number of subjects: 17
Study 34831332 — intervention group
Group type: COMPARATOR
Intervention: Severe hypoglycemia
Number of subjects: 17
Study 34831493 — intervention group
Group type: EXPERIMENTAL
Intervention: Online questionnaire measuring perceived stress, depression, anxiety, and resilience completed by mothers two months postpartum during the COVID-19 pandemic.
Number of subjects: 0
Study 34831493 — intervention group
Group type: COMPARATOR
Intervention: Online questionnaire measuring perceived stress, depression, anxiety, and resilience completed by mothers two months postpartum before the COVID-19 pandemic.
Number of subjects: 0
Study 34831933 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial centre-based with non-parents (PCN)
Number of subjects: 540
Study 34831933 — intervention group
Group type: COMPARATOR
Intervention: Full-time centre-based childcare (FC)
Number of subjects: 540
Study 34831933 — intervention group
Group type: COMPARATOR
Intervention: Partial centre-based with parental care (PCP)
Number of subjects: 540
Study 34832978 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023
Number of subjects: 0
Study 34832978 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023 + Menthol
Number of subjects: 0
Study 34832978 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol
Number of subjects: 0
Study 34834511 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Fixed-Dose Combination (SFC) via Elpenhaler for 12 months
Number of subjects: 1016
Study 34835197 — intervention group
Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC (whole-virion inactivated SARS-CoV-2 vaccine candidate)
Number of subjects: 3
Study 34835197 — intervention group
Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC
Number of subjects: 3
Study 34836422 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the DASH diet/Mediterranean diet
Number of subjects: 6209
Study 34836504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic COVID
Number of subjects: 1649
Study 34836504 — intervention group
Group type: COMPARATOR
Intervention: PreCOVID
Number of subjects: 1649
Study 34836755 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis catheters placed at the pancreaticojejunostomy and hepaticojejunostomy
Number of subjects: 35
Study 34836902 — intervention group
Group type: EXPERIMENTAL
Intervention: A Better everyday LifE (ABLE)
Number of subjects: 80
Study 34836902 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational therapy
Number of subjects: 80
Study 34836903 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial impact assessment through a 74-question questionnaire
Number of subjects: 56656
Study 34836903 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological impact measures including depression, anxiety, stress, and post-traumatic stress disorder scores
Number of subjects: 56656
Study 34836904 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise and PA intervention with support from an exercise specialist and additional support from a smartwatch and phone app
Number of subjects: 120
Study 34836904 — intervention group
Group type: COMPARATOR
Intervention: Active control (structured exercise and PA intervention supported by an exercise specialist)
Number of subjects: 120
Study 34836904 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative process evaluation and piloting of potential clinical outcome measures for a future RCT
Number of subjects: 120
Study 34836907 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) monthly
Number of subjects: 624
Study 34836907 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) weekly
Number of subjects: 624
Study 34836907 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) biweekly
Number of subjects: 624
Study 34836907 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 624
Study 34836908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) and high-intensity statins (atorvastatin or rosuvastatin) within 24 hours of stroke onset, followed by aspirin or clopidogrel alone from day 22.
Number of subjects: 138
Study 34836908 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy without high-intensity statin treatment (historical control).
Number of subjects: 138
Study 34837141 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask during maximal exercise test
Number of subjects: 26
Study 34837141 — intervention group
Group type: COMPARATOR
Intervention: No mask during maximal exercise test
Number of subjects: 26
Study 34837160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer
Number of subjects: 4613
Study 34837160 — intervention group
Group type: COMPARATOR
Intervention: Frozen embryo transfer
Number of subjects: 4613
Study 34837382 — intervention group
Group type: EXPERIMENTAL
Intervention: Roselle extract capsules (total dose of 5600 mg)
Number of subjects: 60
Study 34837382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study 34837522 — intervention group
Group type: EXPERIMENTAL
Intervention: PLANT (30% animal-source protein/70% plant-source protein)
Number of subjects: 136
Study 34837522 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 (50% animal-source protein/50% plant-source protein)
Number of subjects: 136
Study 34837522 — intervention group
Group type: COMPARATOR
Intervention: 50/50 and PLANT
Number of subjects: 136
Study 34837522 — intervention group
Group type: EXPERIMENTAL
Intervention: PLANT
Number of subjects: 136
Study 34837522 — intervention group
Group type: COMPARATOR
Intervention: ANIMAL (70% animal-source protein/30% plant-source protein)
Number of subjects: 136